Sun.Jun 01, 2025

article thumbnail

AstraZeneca drug could help keep a common breast cancer at bay

BioPharma Drive: Drug Pricing

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of initial treatment, potentially opening a novel step in patient care.

Drugs 285
article thumbnail

How Caffeine Affects Your Brain While You Sleep

Drugs.com

SUNDAY, June 1, 2025 Your morning cup of coffee might help you power through the day but could it be keeping your brain too alert at night, even while you sleep?A new study suggests that caffeine doesnt just affect your energy levels. It may al.

168
168
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising

BioPharma Drive: Drug Pricing

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a bispecific antibody newly licensed by Pfizer.

Licensing 162
article thumbnail

Adobe Sensei and GenAI in Practice for Enterprise CMS

Perficient: Drug Development

Adobe Experience Manager (AEM) introduced Adobe Sensei and Generative AI (GenAI) to transform enterprise content management by automating, personalizing, and scaling content creation and delivery. These AI capabilities help marketers, content creators, and enterprises produce highly relevant and engaging digital experiences faster and more efficiently.

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Senator Durbin Has Questions About FDA’s “Operational Capacity” to Oversee DTC Prescription Drug Advertising Amid Workforce Reductions – Don’t We All?

FDA Law Blog: Biosimilars

By Charles D. Snow & Dara Katcher Levy In a recent letter to FDA Commissioner Dr. Martin Makary, U.S. Senator Dick Durbin (D-IL) expressed concerns over the agencys ability to regulate direct-to-consumer (DTC) prescription drug advertisements following recent workforce reductions. In his letter, Senator Durbin highlighted FDAs critical role in ensuring that pharmaceutical advertisements are truthful, not misleading, and provide balanced information and asked a number of questions including